Tak Casey, Thompson Paige, Morse Jessica L, McCallum Meaghan
Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA.
Noom Inc., Princeton, New Jersey, USA.
Obesity (Silver Spring). 2025 Sep;33(9):1637-1644. doi: 10.1002/oby.24337. Epub 2025 Aug 14.
The objective of this study was to compare health care resource utilization (HRU), health care costs, and glucagon-like peptide-1 (GLP-1) agonist use among working US adults who engaged in Noom Weight, a smartphone-based lifestyle intervention for weight management, to individuals offered Noom who did not enroll.
Insurance claims data were used to conduct retrospective analyses of 723 Noom participants matched via propensity scores and compared to 723 non-Noom participants at 6 months post index.
Compared to nonparticipants, Noom participants had significantly lower HRU, medical and pharmacy costs, and GLP-1 agonist use in the 6-month post-index period. On average, Noom participants had 3.2 fewer outpatient visits, 0.34 fewer emergency department visits, 0.25 fewer inpatient visits, and 0.012 fewer surgeries than non-Noom participants (all p values <0.001). Noom participants' health care costs were $831 lower than non-Noom participants. Relative to non-Noom users, Noom participants also had 42% fewer claims for GLP-1 agonists (p = 0.02).
Compared to matched nonparticipants, Noom participation was associated with lower HRU, health care costs, and GLP-1 agonist use at 6 months post index. Results of this study support Noom as a cost-effective and HRU-lowering digital weight-management program for working adults in the United States.
本研究的目的是比较参与Noom Weight（一种基于智能手机的体重管理生活方式干预项目）的美国在职成年人与收到Noom邀请但未注册的个体之间的医疗保健资源利用（HRU）、医疗保健成本和胰高血糖素样肽-1（GLP-1）激动剂的使用情况。
利用保险理赔数据对723名通过倾向得分匹配的Noom参与者进行回顾性分析，并与索引后6个月的723名非Noom参与者进行比较。
与未参与者相比，Noom参与者在索引后6个月期间的HRU、医疗和药房成本以及GLP-1激动剂的使用显著更低。平均而言，Noom参与者的门诊就诊次数比非Noom参与者少3.2次，急诊就诊次数少0.34次，住院就诊次数少0.25次，手术次数少0.012次（所有p值<0.001）。Noom参与者的医疗保健成本比非Noom参与者低831美元。相对于非Noom使用者，Noom参与者的GLP-1激动剂索赔也少42%（p = 0.02）。
与匹配的未参与者相比，参与Noom与索引后6个月时较低的HRU、医疗保健成本和GLP-1激动剂使用相关。本研究结果支持Noom作为一种对美国在职成年人具有成本效益且能降低HRU的数字体重管理项目。
